Understanding how RAD51 helps maintain DNA stability in cancer cells
Official title: Molecular modulator of RAD51 in maintaining genome stability
Funded at Rosalind Franklin Univ of Medicine & Sci · NIH-11071468 · Data updated 2026-11-12
This study looks at how a protein called RAD51 helps keep cancer cells healthy by protecting their DNA during stressful times, which could lead to better treatments for patients, especially those with certain genetic changes like BRCA mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rosalind Franklin Univ of Medicine & Sci NIH-funded |
| Lab location | 1 site (North Chicago, United States) |
| Project start | December 1, 2019 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $388,830 |
| NIH project number | 2R01CA234266-08 |
| Project ID | NIH-11071468 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced cancers, particularly those with BRCA mutations or those experiencing resistance to current cancer therapies.
✕Less likely to help
Patients with early-stage cancers or those whose cancer is not related to DNA repair mechanisms may not benefit from this research.
What this research studies
This research investigates the mechanisms by which RAD51, a protein involved in DNA repair, helps maintain genome stability in cancer cells. It focuses on how cells protect stalled DNA replication forks from degradation, which is crucial for cell survival and cancer therapy effectiveness. The study employs advanced techniques like cryo-electron microscopy to visualize the interactions between RAD51 and other proteins involved in this protective process. By uncovering these mechanisms, the research aims to improve cancer treatment strategies, particularly for patients with specific genetic backgrounds like those with BRCA mutations.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that enhance the stability of DNA in cancer cells, potentially improving treatment outcomes.
How similar studies have gone: Other research has shown promise in understanding DNA repair mechanisms, but this specific approach focusing on RAD51 and calcium signaling is relatively novel.
Where this research is happening
-
Rosalind Franklin Univ of Medicine & Sci
North Chicago, United States Active
Researchers
- Principal investigator: Chai, Weihang — Rosalind Franklin Univ of Medicine & Sci
- Study coordinator: Chai, Weihang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.